The Effect of Roux-en-Y vs. Omega-Loop Gastric Bypass on Liver, Metabolic Parameters, and Weight Loss

Obesity Surgery

Volumn 26, Issue 9, 2016, Pages 2204-2212

  Kruschitz, Renate ^a,c   Luger, Maria ^a,b   Kienbacher, Christian ^a   Trauner, Michael ^a   Klammer, Carmen ^a   Schindler, Karin ^a   Langer, Felix B ^a   Prager, Gerhard ^a   Krebs, Michael ^a   Ludvik, Bernhard ^a,c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Special Institute for Preventive Cardiology and Nutrition   (Austria)

^c KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

Author keywords

Gastric bypass; Liver parameters; Metabolic parameters; Morbid obesity; Weight loss

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; INSULIN; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; COHORT ANALYSIS; COMPARATIVE STUDY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTRIC BYPASS SURGERY; HUMAN; INSULIN RESISTANCE; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; MORBID OBESITY; OMEGA LOOP GASTRIC BYPASS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTHROMBIN TIME; RETROSPECTIVE STUDY; ROUX Y ANASTOMOSIS; SENSITIVITY ANALYSIS; SURGICAL TECHNIQUE; WEIGHT REDUCTION; BLOOD; CHEMISTRY; LIVER; METABOLISM; PHYSIOLOGY; PROCEDURES; STATISTICS AND NUMERICAL DATA;

BIOMARKERS; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; GASTRIC BYPASS; HUMANS; INSULIN RESISTANCE; LIVER; MALE; OBESITY, MORBID; RETROSPECTIVE STUDIES; TRIGLYCERIDES; WEIGHT LOSS;

EID: 84961843803     PISSN: 09608923     EISSN: 17080428     Source Type: Journal    
DOI: 10.1007/s11695-016-2083-6     Document Type: Article

References (42)

1. Buchwald H, Oien DM. Metabolic/bariatric surgery worldwide 2008. Obes Surg. 2009;19(12):1605–11.
2. Sjöström L, Narbro K, Sjöström CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357(8):741–52.
3. Mechanick JI, Kushner RF, Sugerman HJ, et al. The Obesity Society and American Society for Metabolic & Bariatric Surgery medical guidelines for clinical practice for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient. Obesity. 2009;17(1):1–70.
4. Gagnon LE, Karwacki Sheff EJ. Outcomes and complications after bariatric surgery: a randomized study of gastric bypass and duodenal switch. Am J Nurs. 2012;112(9):26–36.
5. Disse E, Pasquer A, Espalieu P, et al. Greater weight loss with the omega loop bypass compared to the Roux-en-Y gastric bypass: a comparative study. Obes Surg. 2014;24:841–6.
6. Lee WJ, Yu PJ, Wang W, et al. Laparoscopic Roux-en-Y versus mini-gastric bypass for the treatment of morbid obesity: a prospective randomized controlled clinical trial. Ann Surg. 2005;242:20–8.
7. Rutledge R, Walsh TR. Continued excellent results with the mini-gastric bypass: six-year study in 2,410 patients. Obes Surg. 2005;15:1304–8.
8. Burza MA, Romeo S, Kotronen A, et al. Long-term effect of bariatric surgery on liver enzymes in the Swedish Obese Subjects (SOS) study. PLOS One. 2013;8(3).
9. Wolf AM, Busch B, Kuhlmann HW, et al. Histological changes in the liver of morbidly obese patients: correlation with metabolic parameters. Obes Surg. 2005;15:225–37.
10. Svane MS, Madsbad S. Bariatric surgery—effects on obesity and related co-morbidities. Curr Diabetes Rev. 2014;10:208–14.
11. Hafeez S, Mohamed HA. Bariatric surgery as potential treatment for nonalcoholic fatty liver disease: a future treatment by choice or by chance? J Obes. 2013.
12. D’Albuquerque LA, Gonzalez AM, Wahle RC, et al. Liver transplantation for subacute hepatocellular failure due to massive steatohepatitis after bariatric surgery. Liver Transpl. 2008;14:881–5.
13. Sagredo S, Brahm J, Uribe M, et al. Acute liver failure after bariatric surgery. A case report and literature review. Gastroenterol Hepatol. 2013;36:76–80.
14. Sgambato D, Cotticelli G, de Sio I, et al. Liver failure in an obese middle-aged woman after biliointestinal bypass. World J Clin Cases. 2013;16(1):52–5.
15. Dale O, Salo M. The Helsinki Declaration, research guidelines and regulations: present and future editorial aspects. Acta Anaesthesiol Scand. 1996;40(7):771–2.
16. Fried M, Yumuk V, Oppert JM, et al. Interdisciplinary European guidelines on metabolic and bariatric surgery. Obes Surg. 2014;24(1):42–55.
17. Luger M, Kruschitz R, Langer F, et al. Effects of omega-loop gastric bypass on vitamin D and bone metabolism in morbidly obese bariatric patients. Obes Surg. 2015;25(6):1056–62.
18. Kruschitz R, Luger M, Kienbacher C, et al. Acute weight loss following omega-loop-gastric bypass surgery transiently impairs liver function in diabetic and non-diabetic patients. Wien Klin Wochenschr. 2014;126 Suppl 4:171–98.
19. Rutledge R. The mini-gastric bypass: experience with the first 1.274 cases. Obes Surg. 2001;11(3):276–80.
20. Pepy MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111:1805–12.
21. Kotronen A, Peltonen M, Hakkarainen A, et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology. 2009;137:865–72.
22. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846–54.
23. Angulo P, Keach JC, Batts KP, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999;30:1356–62.
24. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27(6):1487–95.
25. Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group. The metabolic syndrome—a new worldwide definition. Lancet. 2005;366:1059–62.
26. Ratziu V, Giral P, Charlotte F, et al. Liver fibrosis in overweight patients. Gastroenterology. 2000;118(6):1117–23.
27. Deitel M, Greenstein RJ. Recommandations for reporting weight loss. Obes Surg. 2003;13(2):159–60.
28. Chevallier JM, Arman GA, Guenzi M, et al. One thousand single anastomosis (omega loop) gastric bypasses to treat morbid obesity in a 7-year period: outcomes show few complications and good efficacy. obes surg. 2015;25:951–8.
29. Noun R, Skaff J, Riachi E, et al. One thousand consecutive mini-gastric bypass: short- and long-term outcome. Obes Surg. 2012;22:697–703.
30. Victorzon M. Single-anastomosis gastric bypass: better, faster, and safer? Scand J Surg. 2014;104:48–53.
31. Gasteyger C, Larsen TM, Vercruysse F, et al. Effect of a dietary-induced weight loss on liver enzymes in obese subjects. Am J Clin Nutr. 2008;87:1141–7.
32. Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis (NASH). Hepatology. 2010;51(1):121–9.
33. Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, et al. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev. 2010;2010(1).
34. Luyckx FH, Desaive C, Thiry A, et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes. 1998;22:222–6.
35. Wolf AM, Beisiegel U. The Effect of loss of excess weight on the metabolic risk factors after bariatric surgery in morbidly and super-obese patients. Obes Surg. 2007;17:910–9.
36. Kim HC, Nam CM, Jee SH, et al. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ. 2004;328:983.
37. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;98:960–7.
38. Bo S, Gambino R, Durazzo M, et al. Associations between γ-glutamyl transferase, metabolic abnormalities and inflammation in healthy subjects from a population-based cohort: a possible implication for oxidative stress. World J Gastroenterol. 2005;11(45):7109–17.
39. Ghouri N, Preiss D, Sattar N. Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data. Hepatology. 2010;52:1156–61.
40. Torgerson JS, Lindroos AK, Sjöström CD, et al. Are elevated aminotransferases and decreased bilirubin additional characteristics of the metabolic syndrome? Obesity Res. 1997;5(105–114).
41. Johnston DEJ. Special considerations in interpreting liver function tests. Am Fam Physician. 1999;59(8):2223–30.
42. Fuchs CD, Claudel T, Trauner M. Role of metabolic lipases and lipolytic metabolites in the pathogenesis of NAFLD. Trends Endocrinol Metab. 2014;25(11):576–85.